<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thiazolidinediones in the treatment of type 2 diabetes mellitus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thiazolidinediones in the treatment of type 2 diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Thiazolidinediones in the treatment of type 2 diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Silvio E Inzucchi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beatrice Lupsa, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The thiazolidinediones increase insulin sensitivity by acting on adipose, muscle, and, to a lesser extent, liver to increase glucose utilization and decrease glucose production. Two thiazolidinediones (<a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> and <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>) are currently available in the United States. In 2010, the European Medicines Agency suspended sales of rosiglitazone, and in June 2011, the French and German Medicines Agencies also suspended the use of pioglitazone, owing to concerns that the overall risks of rosiglitazone and pioglitazone exceed their benefits. A third thiazolidinedione, troglitazone, was the first drug in this class and was removed from markets because it caused liver dysfunction and, in some patients, liver failure.</p><p>The pharmacology and use of thiazolidinediones will be reviewed here. Other oral anti-hyperglycemic medications are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-120430">(Related Pathway(s):  <a class="utd-content-120430" href="/pathway/120430?topicRef=1757&amp;source=see_link">Diabetes: Initial therapy for non-pregnant adults with type 2 DM</a>.)</span></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-129531">(Related Pathway(s):  <a class="utd-content-129531" href="/pathway/129531?topicRef=1757&amp;source=see_link">Diabetes: Medication selection for non-pregnant adults with type 2 DM and persistent hyperglycemia despite monotherapy</a>.)</span></p><p></p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>The thiazolidinediones increase insulin sensitivity by acting on adipose tissue and muscle to increase glucose utilization. To a lesser degree, they decrease glucose production by the liver [<a href="#rid1">1,2</a>]. The mechanism by which the thiazolidinediones exert their effect is not fully understood. They bind to and activate one or more peroxisome proliferator-activated receptors (PPARs), mostly PPAR-gamma, which alters the transcription of multiple genes involved in glucose and lipid metabolism [<a href="#rid1">1,3</a>].</p><p>PPAR-gamma is found predominantly in adipose tissue, pancreatic beta cells, vascular endothelium, macrophages, and the central nervous system (CNS) [<a href="#rid4">4</a>]. PPAR-alpha is expressed mostly in liver, heart, skeletal muscle, and vascular walls. The various thiazolidinediones have differential effects on PPAR-gamma and PPAR-alpha. <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">Rosiglitazone</a> is a pure PPAR-gamma agonist, while <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> also exerts some PPAR-alpha effects (similar to fibrates). This may account for the different effects that pioglitazone and rosiglitazone have on lipids and cardiovascular ischemic outcomes (see <a class="local">'Cardiovascular effects'</a> below). Partial PPAR-gamma agonists are under investigation, with the hope that partial activation of the nuclear receptor will reduce adverse events [<a href="#rid5">5</a>].</p><p>In human adipocytes, treatment with thiazolidinediones has been reported to increase expression of genes involved in promoting lipid storage and decrease expression of genes associated with inflammation, such as interleukin (IL)-6 [<a href="#rid6">6</a>]. Thus, the insulin-sensitizing effect of thiazolidinediones may be related in part due to regulation of adipose tissue production of adipokines via PPAR-gamma activation [<a href="#rid7">7</a>].</p><p>In the CNS, PPAR-gamma activation may mediate weight gain by promoting increased feeding, as demonstrated in studies of knockout murine models [<a href="#rid8">8-10</a>]. This finding may account, in part, for the weight gain associated with thiazolidinedione treatment, although a substantial component is likely related to fluid retention that has been documented in patients. (See <a class="local">'Weight gain'</a> below.)</p><p class="headingAnchor" id="H2711285366"><span class="h1">CLINICAL USE</span></p><p class="headingAnchor" id="H466010796"><span class="h2">Potential indications</span><span class="headingEndMark"> — </span>Generally, thiazolidinediones are not prescribed as initial therapy in patients with type 2 diabetes. <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> may rarely have a role as initial therapy in patients who have contraindications to other oral agents (eg, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, sulfonylureas), who decline injectable therapies (eg, insulin, glucagon-like peptide 1 [GLP-1] receptor agonists), and in whom medications like dipeptidyl peptidase 4 (DPP-4) inhibitors or sodium-glucose co-transporter 2 (SGLT2) inhibitors cannot be afforded or are found to be less effective. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Contraindications to or intolerance of metformin'</a>.)</p><p><a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> is more often prescribed as second-line or, more commonly, as third-line therapy, when other oral agents in combination are not resulting in adequate glycemic management, especially when cost is a major concern (pioglitazone is available as a low-cost generic) [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Monotherapy failure'</a>.)</p><p><a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> may still offer an advantage in certain clinical settings; for example, in the context of high risk for hypoglycemia, severe insulin resistance, coexisting nonalcoholic steatohepatitis (NASH) (see <a class="local">'Hepatic benefits'</a> below), or recent stroke. However, risks of weight gain, heart failure, fractures, and lingering concerns about a possible small increase in risk of bladder cancer require careful risk-benefit discussion with the patient. Lower doses should be used when possible to mitigate these potential adverse consequences, particularly weight gain and edema. As a fundamental principle, the choice and doses of type 2 diabetes mellitus therapies should be individualized. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Initial pharmacologic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a> and <a class="local">'Safety'</a> below.)</p><p>In contrast to <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>, <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> is rarely used and is no longer widely available because of the concern about a potential increased risk for cardiovascular events suggested by a controversial meta-analysis of phase III clinical trials [<a href="#rid12">12,13</a>]. In addition, potentially adverse atherogenic effects of rosiglitazone as a consequence of altered lipid levels in comparison with the more widely available pioglitazone make it a less desirable choice. (See <a class="local">'Major cardiovascular events'</a> below.)</p><p class="headingAnchor" id="H3870704582"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Thiazolidinediones should not be used in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure or any evidence of fluid overload</p><p class="bulletIndent1"><span class="glyph">●</span>History of fracture or at high risk for fracture (eg, postmenopausal women with low bone mass)</p><p class="bulletIndent1"><span class="glyph">●</span>Active liver disease (liver transaminases &gt;2.5 times above the upper reference limit), unless NASH is known to be the underlying cause of the elevation</p><p class="bulletIndent1"><span class="glyph">●</span>Active or history of bladder cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 diabetes</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy</p><p class="bulletIndent1"><span class="glyph">●</span>Macular edema</p><p></p><p>Combination therapy with thiazolidinediones and insulin may be particularly problematic due to increased risk of edema and heart failure [<a href="#rid14">14-16</a>]. Thiazolidinediones should be discontinued in patients who develop signs and symptoms of heart failure.</p><p class="headingAnchor" id="H3481871934"><span class="h2">Dosing and monitoring</span><span class="headingEndMark"> — </span>Liver biochemical tests should be measured prior to initiating <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>.</p><p class="bulletIndent1"><span class="glyph">●</span>If liver tests are abnormal and due to NASH, repeat periodically (eg, in three months, and then based on clinical findings). (See <a class="local">'Hepatic benefits'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If liver tests are abnormal and the etiology is unknown, evaluate for etiology and do not initiate <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If liver tests are normal at baseline, routine monitoring is not necessary; liver tests should be measured (and <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> discontinued) if symptoms of liver injury develop (eg, right upper abdominal pain, jaundice).</p><p></p><p>Although hepatotoxicity has been demonstrated with other thiazolidinediones, <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> has been associated only rarely with liver toxicity [<a href="#rid17">17</a>]. (See <a class="local">'Hepatotoxicity'</a> below.) </p><p><a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> is usually initiated at a dose of 15 mg daily. If, after a few weeks, there is inadequate glycemic management based upon fasting blood glucose values, the daily dose can be increased in increments of 15 mg to the maximum dose of 45 mg daily. However, side effects of weight gain and edema increase at higher dosing levels (see <a class="local">'Safety'</a> below). Most clinicians still prescribing this medication keep patients in the 15 to 30 mg dosing range. Dose escalation should be performed gradually (eg, every 4 to 12 weeks) while reassessing the patient for weight gain, edema, and other signs of heart failure.</p><p>Glycated hemoglobin (A1C) should be measured at least twice yearly in patients meeting glycemic goals and more frequently (quarterly) in patients whose therapy has changed or who are not meeting goals. Monitoring glycemia is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/1781.html" rel="external">"Glucose monitoring in the ambulatory management of nonpregnant adults with diabetes mellitus", section on 'Type 2 diabetes'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">GLYCEMIC EFFICACY</span></p><p class="headingAnchor" id="H6"><span class="h2">Monotherapy</span><span class="headingEndMark"> — </span>When thiazolidinediones are used as monotherapy, the expected decrease in A1C is approximately 0.5 to 1.4 percent [<a href="#rid18">18-20</a>]. In a randomized trial comparing <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a>, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, and <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">glyburide</a> as initial therapy for type 2 diabetes, rosiglitazone had a lower incidence of monotherapy failure at five years [<a href="#rid21">21</a>]. However, the difference in A1C levels between the rosiglitazone- and metformin-treated groups was small (approximately 0.1 percent). Treatment with the thiazolidinedione was associated with greater weight gain, peripheral edema, and increases in low-density lipoprotein (LDL) concentrations. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Glycemic efficacy'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Combination therapy</span><span class="headingEndMark"> — </span>In addition to use as monotherapy, the thiazolidinediones have been studied in combination with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, sulfonylureas, insulin, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium-glucose co-transporter 2 (SGLT2) inhibitors [<a href="#rid22">22</a>]. Combination therapy is discussed in detail in separately. (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p>Although the addition of a thiazolidinedione to insulin improves glycemic management compared with insulin monotherapy [<a href="#rid23">23,24</a>], the combination of insulin plus a thiazolidinedione is associated with an increased incidence of weight gain, edema, and heart failure and should be avoided in patients where these may be concerns [<a href="#rid14">14-16</a>].</p><p class="headingAnchor" id="H8"><span class="h1">CARDIOVASCULAR EFFECTS</span><span class="headingEndMark"> — </span>The cardiovascular effects of thiazolidinediones may depend upon the specificity of peroxisome proliferator-activated receptor (PPAR) activation [<a href="#rid25">25</a>]. <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">Rosiglitazone</a> (a pure PPAR-gamma agonist) and <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> (PPAR-gamma with some PPAR-alpha agonist activity) have different effects on lipid concentrations, with pioglitazone exerting a less unfavorable effect (see <a class="local">'Lipids'</a> below). Although both drugs have a similar effect on the incidence of heart failure (both increasing the risk), they appear to have disparate effects on ischemic outcomes [<a href="#rid12">12,26</a>]. (See <a class="local">'Major cardiovascular events'</a> below.)</p><p>The results of the meta-analyses and observational studies suggest increased caution with use of <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> in particular. Any potential cardiovascular benefits of <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> must be weighed against the increased risk of heart failure, weight gain, fluid retention, and fractures [<a href="#rid27">27,28</a>]. (See <a class="local">'Major cardiovascular events'</a> below and <a class="local">'Safety'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">Lipids</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">Rosiglitazone</a> and <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> have similar effects on glycemia, but their effects on serum lipid concentrations are different. Most randomized trials have shown a more favorable lipid profile with pioglitazone [<a href="#rid1">1,29,30</a>]. In a review of six randomized trials, low-density lipoprotein (LDL) cholesterol levels typically remained constant when monotherapy or combination therapy with pioglitazone was used, while increases in LDL cholesterol levels ranging from 8 to 16 percent were observed in studies of rosiglitazone [<a href="#rid1">1</a>]. High-density lipoprotein (HDL) cholesterol levels increased by approximately 10 percent with both drugs. Decreases in triglyceride levels were observed more often with pioglitazone than with rosiglitazone.</p><p class="headingAnchor" id="H1601378185"><span class="h2">Major cardiovascular events</span><span class="headingEndMark"> — </span>In 2010, the US Food and Drug Administration (FDA) imposed marked restrictions on the prescribing of <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> because of concerns about increased risk of acute myocardial infarction (MI) and cardiovascular deaths [<a href="#rid31">31</a>]. These restrictions were largely removed by the FDA in 2013 after a reevaluation of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study [<a href="#rid32">32,33</a>], and the Risk Evaluation and Mitigation Strategy (REMS; aimed at educating clinicians about the cardiovascular side effects of rosiglitazone) was eliminated in 2015 [<a href="#rid34">34</a>]. The absence of an adverse effect of rosiglitazone on cardiovascular risk, however, has not been excluded. Based on this controversy, the drug is no longer widely used. The only thiazolidinedione still used to any degree is <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>.</p><p class="headingAnchor" id="H2441714849"><span class="h3">Heart failure</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">Rosiglitazone</a> and <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> increase the risk of heart failure. In meta-analyses of randomized trials of thiazolidinediones for the treatment or prevention of type 2 diabetes, the estimated relative risk (RR) of heart failure in patients randomly assigned to thiazolidinediones compared with placebo ranged from 1.5 to 2.1 (95% CIs 1.2-2.4 and 1.1-4.1, respectively) [<a href="#rid35">35-37</a>]. In the subsequently published RECORD study, the addition of rosiglitazone to <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> or sulfonylurea in people with type 2 diabetes increased the risk of heart failure compared with combination metformin and sulfonylurea (2.7 versus 1.3 percent, hazard ratio [HR] 2.10, 95% CI 1.35-3.27) [<a href="#rid33">33</a>].</p><p>In retrospective analyses of prescription data obtained from national databases, <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> was associated with a greater risk of adverse heart failure events than <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> [<a href="#rid38">38-40</a>].</p><p class="headingAnchor" id="H429474286"><span class="h3">Atherosclerotic cardiovascular events</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rosiglitazone</strong> – The effect of <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> on the risk of MI is uncertain. Meta-analyses of trials evaluating rosiglitazone for the treatment of diabetes show increases in [<a href="#rid12">12,13,37,41-43</a>] or no evidence of effects on [<a href="#rid44">44,45</a>] MI and other adverse outcomes (morbidity, mortality, quality of life). In the RECORD study mentioned above (see <a class="local">'Heart failure'</a> above), the effect of rosiglitazone on MI was inconclusive (HR for rosiglitazone compared with the active comparators for fatal and nonfatal MI 1.14, 95% CI 0.80-1.63) due to the small number of events and possibly affected by greater statin use in the rosiglitazone group. Rosiglitazone did not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pioglitazone</strong> – <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> does not appear to induce the same atherosclerotic cardiovascular risk profile as <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a>. In fact, it likely decreases the risk of major adverse atherosclerotic cardiovascular events [<a href="#rid26">26,46</a>]. This was illustrated by a meta-analysis of 19 trials of pioglitazone for the treatment of type 2 diabetes [<a href="#rid26">26</a>]. MI occurred in 131 patients (1.5 percent) in the pioglitazone group and 159 (2 percent) in the comparator group (placebo, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, sulfonylurea, rosiglitazone; HR 0.81, 95% CI 0.64-1.02). The primary composite endpoint of death, nonfatal MI, or nonfatal stroke occurred in 4.4 and 5.7 percent of patients in the pioglitazone and control groups, respectively (HR 0.82, 95% CI 0.72-0.94). As in the meta-analyses described above, the majority of trials were not originally intended to assess cardiovascular endpoints, which were collected as adverse events and not uniformly adjudicated.</p><p></p><p class="bulletIndent1">The largest of the trials included in the meta-analysis, however, was specifically designed to evaluate cardiovascular outcomes. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) trial evaluated the effect of <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> on cardiovascular events and mortality in 5238 patients with type 2 diabetes and established macrovascular complications (prior MI, stroke, coronary artery bypass graft [CABG] surgery, acute coronary syndrome, or symptomatic peripheral artery disease) [<a href="#rid47">47</a>]. There was a nonsignificant effect on the predefined primary outcome of the study (composite of all-cause mortality, nonfatal MI and silent MI, stroke, acute coronary syndrome, surgical intervention on coronary or leg arteries, or leg amputation; 19.7 versus 21.7 percent, HR 0.90, 95% CI 0.80-1.02). There was, however, a significant decrease in the main secondary endpoint (composite of all-cause mortality, nonfatal MI, or nonfatal stroke) in the pioglitazone group (11.6 versus 13.6 percent, HR 0.84, 95% CI 0.72-0.98). Hospitalization for heart failure was more frequent in the pioglitazone group, with the number of episodes counterbalancing the decreased number of major adverse cardiovascular events. In subgroup analyses, pioglitazone reduced the risk of subsequent MI in patients with prior MI (5.3 versus 7.2 percent with placebo, HR 0.72, 95% CI 0.52-0.99) [<a href="#rid48">48</a>] and subsequent stroke in those with prior stroke (5.6 versus 10.2 percent with placebo, HR 0.53, 95% CI 0.34-0.85) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">In other trials in patients with insulin resistance and recent stroke or transient ischemic attack, <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> reduced the incidence of acute coronary syndrome and stroke, but increased risk of weight gain, edema, and fracture. The risk of heart failure was not increased, although investigators were allowed to decrease the study drug dose for edema or weight gain during the trial [<a href="#rid50">50-52</a>]. Lower doses of pioglitazone (15 and 30 mg per day) may confer much of the cardiovascular benefit with less adverse effects than the full dose of 45 mg daily [<a href="#rid53">53</a>]. These doses appear to be more commonly used in those who still prescribe this thiazolidinedione.</p><p></p><p class="headingAnchor" id="H2772508175"><span class="h1">HEPATIC BENEFITS</span><span class="headingEndMark"> — </span>In patients with type 2 diabetes mellitus and biopsy-proven nonalcoholic steatohepatitis (NASH), <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> improves fibrosis as well as inflammation and steatosis. This topic is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Patients with NASH and diabetes'</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SAFETY</span><span class="headingEndMark"> — </span>Thiazolidinediones are not considered first-choice agents for patients with type 2 diabetes, due to adverse effects including increased risk of weight gain, fluid retention, heart failure, fractures, and the potential small increased risk of bladder cancer (<a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>). In 2010, the European Medicines Agency suspended sales of <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> [<a href="#rid54">54</a>], and in June 2011, the French and German Medicines Agencies also suspended the use of pioglitazone because of the potential increased risk of bladder cancer and the concern that the overall risks of pioglitazone exceed its benefits. The European Medicines Agency has not suspended the sales of pioglitazone [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Hypoglycemia</span><span class="headingEndMark"> — </span>The thiazolidinediones improve blood glucose primarily by increasing insulin sensitivity. Therefore, thiazolidinedione monotherapy is much less likely to cause hypoglycemia than sulfonylureas or insulin [<a href="#rid18">18,21</a>]. However, hypoglycemic events can occur when these agents are used in conjunction with sulfonylureas or insulin.</p><p class="headingAnchor" id="H20"><span class="h2">Weight gain</span><span class="headingEndMark"> — </span>All of the thiazolidinediones cause weight gain. This effect is both dose- and time-dependent and can be substantial [<a href="#rid18">18,56-61</a>]. In a 26-week trial, the improvement in A1C with <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> was accompanied by a dose-related weight gain of up to 4.5 kg (9.9 pounds) compared with placebo [<a href="#rid19">19</a>]. In a cohort of patients taking <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> continuously for over 30 months, the average weight gain increased steadily up to 30 months but then plateaued (at around 5.3 kg, or 12 pounds) by 36 months [<a href="#rid62">62</a>].</p><p>The weight gain is caused, in part, by fluid retention. A small study (n = 8) found that 12 weeks of therapy with <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> 45 mg resulted in 2.4 liters of water accumulation, which accounted for 75 percent of the 3.1 kg weight gain [<a href="#rid63">63</a>]. (See <a class="local">'Fluid retention/heart failure'</a> below.)</p><p>In addition, weight gain may be due to thiazolidinedione-induced activation of peroxisome proliferator-activated receptor (PPAR)-gamma in the central nervous system (CNS) [<a href="#rid10">10</a>]. In animal studies, activation of CNS PPAR-gamma by <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> increased feeding and expanded adipose tissue mass [<a href="#rid8">8,9</a>].</p><p>In humans, upregulation of genes that facilitate adipocyte lipid storage has been described [<a href="#rid64">64</a>]. Weight gain may also result from the proliferation of new adipocytes. In 20 patients with type 2 diabetes treated with the previously used thiazolidinedione troglitazone, the increase in fat deposition occurred primarily in subcutaneous fat stores, resulting in a decreased visceral-to-subcutaneous fat ratio [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Fluid retention/heart failure</span><span class="headingEndMark"> — </span>Fluid retention, which is more prominent with concomitant insulin therapy, can occur with all the thiazolidinediones but does not account for all of the weight gain. (See <a class="local">'Weight gain'</a> above.)</p><p>Peripheral edema occurs in 4 to 6 percent of patients treated with thiazolidinediones (compared with 1 to 2 percent with placebo) and in a higher percentage of patients with a history of heart failure [<a href="#rid1">1</a>]. This fluid retention may lead to the precipitation or worsening of heart failure. (See <a class="local">'Heart failure'</a> above.)</p><p>As mentioned above, the thiazolidinediones act by binding to and activating PPAR-gamma [<a href="#rid1">1,65</a>]. Along the nephron, PPAR-gamma is most abundant in the collecting tubules, and the fluid retention with thiazolidinediones appears to result from PPAR-gamma stimulation of sodium reabsorption by sodium channels (called the epithelial sodium channel) in the luminal membrane of the collecting tubule cells [<a href="#rid66">66</a>]. This effect is mediated by increased expression of the gamma subunit of the sodium channel gene mRNA.</p><p class="headingAnchor" id="H22"><span class="h2">Skeletal fractures</span><span class="headingEndMark"> — </span>There is an increasing body of evidence suggesting that thiazolidinediones decrease bone density and increase fracture risk, particularly in women [<a href="#rid67">67-75</a>]. In a large population-based study using the United Kingdom-based General Practice Research Database, <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> (odds ratio [OR] 2.59, 95% CI 0.96-7.01) and <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> (OR 2.38, 95% CI 1.39-4.09) were associated with low-trauma fracture in both females and males [<a href="#rid71">71</a>]. The absolute increase in fracture risk associated with thiazolidinedione treatment appears to be small. Nevertheless, these drugs should probably not be used in women with low bone density or other risk factors for fracture (see <a class="local">'Contraindications'</a> above). The results of observational studies in men are conflicting and suggest that additional studies are required to determine if there is a similar increase in fracture risk.</p><p>The adverse impact of thiazolidinediones on bone in patients with type 2 diabetes is illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective review of adverse events in the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) study, there was a higher rate of fractures in women receiving <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> (5.1 versus 2.5 percent with placebo), but not in men [<a href="#rid47">47,74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with insulin resistance and recent stroke or transient ischemic attack, there was an increased risk of fracture in patients receiving <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> (13.6 versus 8.8 percent with placebo, hazard ratio [HR] 1.53, 95% CI 1.24-1.89) [<a href="#rid75">75</a>]. Increased risk for any fracture was observed in both men (9.4 versus 5.2 percent, HR 1.83, 95% CI 1.36-2.48) and women (14.9 versus 11.6 percent, HR 1.32, 95% CI 0.98-1.78). The increased risk of fracture appeared to emerge after two years of pioglitazone therapy.</p><p></p><p>The mechanisms by which thiazolidinediones may affect bone health are not completely understood. Thiazolidinediones activate PPAR-gamma, and both isoforms of PPAR-gamma are expressed in bone.</p><p>Activation of PPAR-gamma 2 results in diversion of bone marrow stromal cells from the osteoblast lineage into the adipocyte lineage, which subsequently leads to a decrease in bone formation rates and increase in adipogenesis [<a href="#rid76">76</a>]. Activation of PPAR-gamma 1 enhances the formation and activity of osteoclasts [<a href="#rid77">77</a>]. Thiazolidinediones have also been reported to induce osteocyte apoptosis [<a href="#rid78">78</a>]. Most clinical trials suggest a diminution in bone formation and an increase in bone resorption and slight decrease in bone density with thiazolidinedione use [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H12774482"><span class="h2">Bladder cancer</span><span class="headingEndMark"> — </span>Although there are no data linking <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> to bladder cancer, there is concern about increased risk with <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>. The association is controversial, and different reports have yielded conflicting results. Pioglitazone should not be used in patients with active bladder cancer [<a href="#rid80">80</a>]. In patients with a history of bladder cancer, the benefits of glycemic management versus the unknown risk for cancer recurrence with pioglitazone should be considered. (See <a class="local">'Contraindications'</a> above.)</p><p>In preclinical studies, <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> was associated with bladder tumors in male rats. In the PROactive trial described above, there were more cases of bladder cancer (14 versus 5) in the pioglitazone than placebo group [<a href="#rid74">74</a>]. In a 10-year observational study of pioglitazone use in patients with diabetes, there was not a significant association between pioglitazone exposure and increases risk of bladder cancer (HR 1.06, 95% CI 0.89-1.26) even when accounting for dose and duration of exposure [<a href="#rid81">81</a>].</p><p>A meta-analysis involving 26 separate studies concluded that there is no increased risk of bladder cancer with <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> use (HR 1.07, 95% CI 0.96-1.18) [<a href="#rid82">82</a>]. Another meta-analysis of two randomized controlled studies and 20 observational studies suggested that pioglitazone was associated with slightly but significantly increased risk of bladder cancer (for randomized studies OR 1.84, 95% CI 0.99-3.42; for observational studies OR 1.13, 95% CI 1.03-1.25), which were time and dose dependent [<a href="#rid83">83</a>]. These conflicting results have resulted in uncertainty about the association between pioglitazone and bladder cancer. If an association exists, it is likely to be very small. Nonetheless, this controversy should be discussed with patients prior to initiation of therapy. There are no broad recommendations about screening for bladder cancer in patients on long-term pioglitazone therapy. Any signs of this condition (eg, hematuria) should be evaluated promptly.</p><p class="headingAnchor" id="H2872758"><span class="h2">Hepatotoxicity</span><span class="headingEndMark"> — </span>The thiazolidinedione troglitazone was removed from the market in the United States and United Kingdom because of reports of severe hepatocellular injury [<a href="#rid84">84</a>], resulting in death or the need for liver transplantation in some patients [<a href="#rid85">85,86</a>]. Similar hepatoxicity has not been observed with <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">rosiglitazone</a> or <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a> [<a href="#rid87">87</a>]. Nonetheless, based on the troglitazone experience, the US Food and Drug Administration (FDA) currently recommends that patients receiving pioglitazone or rosiglitazone undergo baseline liver biochemical testing followed by periodic monitoring of liver function based upon clinical judgement (see <a class="local">'Dosing and monitoring'</a> above). In patients with nonalcoholic fatty liver disease, transaminase levels often improve with use of thiazolidinediones, which correlates with their known effects to decrease liver fat content. (See  <a class="medical medical_review" href="/z/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Patients with NASH and diabetes'</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Macular edema</span><span class="headingEndMark"> — </span>Macular edema has been reported in patients taking thiazolidinediones, though the frequency of occurrence is unknown [<a href="#rid88">88-92</a>]. In a prospective cohort study of 172,006 individuals with diabetic macular edema (DME), the use of thiazolidinediones (98 percent with <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">pioglitazone</a>) was associated with a 2.6-fold increased risk of developing DME, and this relationship remained even after correcting for potential confounders, such as age or poor glycemic management [<a href="#rid89">89</a>]. However, in the randomized clinical trial Action to Control Cardiovascular Risk in Diabetes (ACCORD) eye substudy, data from a subgroup of 3473 participants who had fundus photographs that were centrally evaluated in a standard fashion did not demonstrate a conclusive link between thiazolidinedione use and DME [<a href="#rid89">89,93</a>]. Thus, data suggest that DME can occur at least sporadically in patients with diabetes mellitus treated with thiazolidinedione, but this is relatively rare and may be related to underlying confounders, such as duration or severity of diabetes. Patients at greatest risk seem to be those who are also at risk for peripheral edema. (See <a class="local">'Fluid retention/heart failure'</a> above.)</p><p class="headingAnchor" id="H26"><span class="h1">DIABETES PREVENTION</span><span class="headingEndMark"> — </span>We do not suggest using thiazolidinediones for diabetes prevention. (See  <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus", section on 'Our approach'</a>.)</p><p>Several studies have suggested efficacy in preventing type 2 diabetes in patients at risk, at least while thiazolidinedione therapy is continued [<a href="#rid94">94-97</a>]. Although thiazolidinediones delay the onset of diagnosis of diabetes and, therefore, reduce the length of exposure of hyperglycemia, the benefit or harm of the intervention (independent of the effect on hyperglycemia) must be considered. Thiazolidinediones are limited by adverse effects (see <a class="local">'Safety'</a> above). Thus, the risks may outweigh the benefits.</p><p class="headingAnchor" id="H2250151397"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104442.html" rel="external">"Society guideline links: Diabetes mellitus in adults"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – The thiazolidinediones increase insulin sensitivity by acting on adipose tissue and muscle to increase glucose utilization. To a lesser degree, they decrease glucose production by the liver. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential indications</strong> – In general, thiazolidinediones are not prescribed as initial therapy in patients with type 2 diabetes. (See <a class="local">'Potential indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> may rarely have a role as initial therapy in patients who have contraindications to other oral agents (eg, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, sulfonylureas), who decline injectable therapies (eg, insulin, glucagon-like peptide 1 [GLP-1] receptor agonists), and in whom medications like dipeptidyl peptidase 4 (DPP-4) inhibitors or sodium-glucose co-transporter 2 (SGLT2) inhibitors cannot be afforded or are found to be less effective. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Contraindications to or intolerance of metformin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> is more often prescribed as second-line or, more commonly as third-line therapy, when other oral agents in combination are not resulting in adequate glycemic management, especially when cost is a major concern (pioglitazone is available as a low-cost generic). (See  <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Without established cardiovascular or kidney disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> may also play a role in certain clinical settings; for example, in the context of high risk for hypoglycemia, severe insulin resistance, coexisting nonalcoholic steatohepatitis (NASH), or potentially, recent stroke. However, the risk of weight gain, heart failure, and fractures, and the concerns regarding bladder cancer need to be considered. (See <a class="local">'Safety'</a> above and  <a class="medical medical_review" href="/z/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Patients with NASH and diabetes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycemic efficacy</strong> – When used as monotherapy, thiazolidinediones reduce glycated hemoglobin (A1C) values by approximately 0.5 to 1.4 percentage points. (See <a class="local">'Glycemic efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular outcomes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">Rosiglitazone</a> is rarely used (and is no longer widely available) because of the increased risk of heart failure and concern for increased risk of atherosclerotic cardiovascular events. (See <a class="local">'Major cardiovascular events'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">Pioglitazone</a> increases the risk of heart failure but likely decreases the risk of major adverse atherosclerotic cardiovascular events. (See <a class="local">'Major cardiovascular events'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes prevention</strong> – We suggest <strong>not</strong> using thiazolidinediones for type 2 diabetes prevention (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Instead, we focus on lifestyle change and, in selected patients, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>. (See <a class="local">'Diabetes prevention'</a> above and  <a class="medical medical_review" href="/z/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H2205592608"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106.</a></li><li><a class="nounderline abstract_t">Petersen KF, Krssak M, Inzucchi S, et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49:827.</a></li><li><a class="nounderline abstract_t">Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18 Suppl 2:S10.</a></li><li><a class="nounderline abstract_t">Yasmin S, Jayaprakash V. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present. Eur J Med Chem 2017; 126:879.</a></li><li><a class="nounderline abstract_t">Kaserer T, Obermoser V, Weninger A, et al. Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists. Eur J Med Chem 2016; 124:49.</a></li><li><a class="nounderline abstract_t">Kolak M, Yki-Järvinen H, Kannisto K, et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 2007; 92:720.</a></li><li><a class="nounderline abstract_t">Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92:386.</a></li><li><a class="nounderline abstract_t">Ryan KK, Li B, Grayson BE, et al. A role for central nervous system PPAR-γ in the regulation of energy balance. Nat Med 2011; 17:623.</a></li><li><a class="nounderline abstract_t">Lu M, Sarruf DA, Talukdar S, et al. Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 2011; 17:618.</a></li><li><a class="nounderline abstract_t">Myers MG Jr, Burant CF. PPAR-γ action: it's all in your head. Nat Med 2011; 17:544.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43:S98.</a></li><li><a class="nounderline abstract_t">Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457.</a></li><li><a class="nounderline abstract_t">Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170:1191.</a></li><li class="breakAll">US Food and Drug Administration. MedWatch the FDA Safety Information and Adverse Event Reporting Program - Avandia (rosiglitazone), April 2002. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154468.htm (Accessed on June 13, 2012).</li><li><a class="nounderline abstract_t">Lu Y, Ma D, Xu W, et al. Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis. J Diabetes Investig 2015; 6:78.</a></li><li><a class="nounderline abstract_t">Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 2005; 7:633.</a></li><li><a class="nounderline abstract_t">Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27:305.</a></li><li><a class="nounderline abstract_t">Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23:1605.</a></li><li><a class="nounderline abstract_t">Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86:280.</a></li><li><a class="nounderline abstract_t">Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24:308.</a></li><li><a class="nounderline abstract_t">Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427.</a></li><li><a class="nounderline abstract_t">Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164:740.</a></li><li><a class="nounderline abstract_t">Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24:1226.</a></li><li><a class="nounderline abstract_t">Tan A, Cao Y, Xia N, et al. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis. Eur J Intern Med 2010; 21:398.</a></li><li><a class="nounderline abstract_t">Friedland SN, Leong A, Filion KB, et al. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med 2012; 125:126.</a></li><li><a class="nounderline abstract_t">Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180.</a></li><li><a class="nounderline abstract_t">Bloomgarden ZT. The Avandia debate. Diabetes Care 2007; 30:2401.</a></li><li><a class="nounderline abstract_t">Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121:1868.</a></li><li><a class="nounderline abstract_t">Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097.</a></li><li><a class="nounderline abstract_t">Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547.</a></li><li class="breakAll">US Food and Drug Administration. Q&amp;A: Avandia (rosiglitazone). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226976.htm (Accessed on September 24, 2010).</li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm (Accessed on December 02, 2013).</li><li><a class="nounderline abstract_t">Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373:2125.</a></li><li class="breakAll">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm477601.htm (Accessed on December 17, 2015).</li><li><a class="nounderline abstract_t">Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30:2148.</a></li><li><a class="nounderline abstract_t">Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370:1129.</a></li><li><a class="nounderline abstract_t">Wallach JD, Wang K, Zhang AD, et al. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ 2020; 368:l7078.</a></li><li><a class="nounderline abstract_t">Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168:2368.</a></li><li><a class="nounderline abstract_t">Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009; 339:b2942.</a></li><li><a class="nounderline abstract_t">Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304:411.</a></li><li><a class="nounderline abstract_t">Rosen CJ. The rosiglitazone story--lessons from an FDA Advisory Committee meeting. N Engl J Med 2007; 357:844.</a></li><li><a class="nounderline abstract_t">Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298:1189.</a></li><li><a class="nounderline abstract_t">Cobitz A, Zambanini A, Sowell M, et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Saf 2008; 17:769.</a></li><li><a class="nounderline abstract_t">Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; :CD006063.</a></li><li><a class="nounderline abstract_t">Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147:578.</a></li><li><a class="nounderline abstract_t">Zhou Y, Huang Y, Ji X, et al. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279.</a></li><li><a class="nounderline abstract_t">Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49:1772.</a></li><li><a class="nounderline abstract_t">Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38:865.</a></li><li><a class="nounderline abstract_t">Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 374:1321.</a></li><li><a class="nounderline abstract_t">Young LH, Viscoli CM, Curtis JP, et al. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. Circulation 2017; 135:1882.</a></li><li><a class="nounderline abstract_t">Yaghi S, Furie KL, Viscoli CM, et al. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Circulation 2018; 137:455.</a></li><li><a class="nounderline abstract_t">Spence JD, Viscoli C, Kernan WN, et al. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes Obes Metab 2022; 24:1150.</a></li><li class="breakAll">European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim - September 23, 2010. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1&amp;jsenabled=true (Accessed on September 24, 2010).</li><li class="breakAll">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002277/human_med_001491.jsp&amp;mid=WC0b01ac058001d124 (Accessed on February 15, 2017).</li><li><a class="nounderline abstract_t">Fonseca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab 1998; 83:3169.</a></li><li><a class="nounderline abstract_t">Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:176.</a></li><li><a class="nounderline abstract_t">Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338:861.</a></li><li><a class="nounderline abstract_t">Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867.</a></li><li><a class="nounderline abstract_t">Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695.</a></li><li><a class="nounderline abstract_t">Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23:1067.</a></li><li><a class="nounderline abstract_t">King A, Armstrong D, Chinnapongse S. Clinical observations of weight gain associated with pioglitazone: 3 years. Diabetes 2003; 52 (Suppl 1):A123.</a></li><li><a class="nounderline abstract_t">Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006; 29:510.</a></li><li><a class="nounderline abstract_t">Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004; 27:1660.</a></li><li><a class="nounderline abstract_t">Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99:2416.</a></li><li><a class="nounderline abstract_t">Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11:861.</a></li><li><a class="nounderline abstract_t">Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19:129.</a></li><li><a class="nounderline abstract_t">Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91:3349.</a></li><li><a class="nounderline abstract_t">Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92:1305.</a></li><li><a class="nounderline abstract_t">Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30:1574.</a></li><li><a class="nounderline abstract_t">Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168:820.</a></li><li><a class="nounderline abstract_t">Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95:592.</a></li><li><a class="nounderline abstract_t">Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010; 95:4560.</a></li><li><a class="nounderline abstract_t">Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32:187.</a></li><li><a class="nounderline abstract_t">Viscoli CM, Inzucchi SE, Young LH, et al. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. J Clin Endocrinol Metab 2017; 102:914.</a></li><li><a class="nounderline abstract_t">Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145:401.</a></li><li><a class="nounderline abstract_t">Wei W, Zeve D, Wang X, et al. Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population. Mol Cell Biol 2011; 31:4692.</a></li><li><a class="nounderline abstract_t">Sorocéanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004; 183:203.</a></li><li><a class="nounderline abstract_t">Billington EO, Grey A, Bolland MJ. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia 2015; 58:2238.</a></li><li class="breakAll">US Food and Drug Administration. FDA drug safety communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer - June 15, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm (Accessed on June 16, 2011).</li><li><a class="nounderline abstract_t">Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA 2015; 314:265.</a></li><li><a class="nounderline abstract_t">Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis. Diabetes Ther 2017; 8:705.</a></li><li><a class="nounderline abstract_t">Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med 2018; 7:1070.</a></li><li><a class="nounderline abstract_t">Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338:916.</a></li><li><a class="nounderline abstract_t">Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129:36.</a></li><li><a class="nounderline abstract_t">Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 1998; 129:38.</a></li><li><a class="nounderline abstract_t">Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 2009; 32:787.</a></li><li><a class="nounderline abstract_t">Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2005; 123:1273.</a></li><li><a class="nounderline abstract_t">Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009; 147:583.</a></li><li><a class="nounderline abstract_t">Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med 2012; 172:1005.</a></li><li><a class="nounderline abstract_t">Singh S, Segal JB. Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes". Arch Intern Med 2012; 172:1011.</a></li><li><a class="nounderline abstract_t">Kendall C, Wooltorton E. Rosiglitazone (Avandia) and macular edema. CMAJ 2006; 174:623.</a></li><li><a class="nounderline abstract_t">ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364:1104.</a></li><li><a class="nounderline abstract_t">DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096.</a></li><li><a class="nounderline abstract_t">DREAM Trial Investigators. Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care 2011; 34:1265.</a></li><li><a class="nounderline abstract_t">Inzucchi SE, Viscoli CM, Young LH, et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016; 39:1684.</a></li></ol></div><div id="topicVersionRevision">Topic 1757 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356308" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thiazolidinediones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10905493" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mechanism of troglitazone action in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11921433" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The mode of action of thiazolidinediones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988463" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27560282" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR)γpartial agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17148569" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17148564" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21532595" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A role for central nervous system PPAR-γin the regulation of energy balance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21532596" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Brain PPAR-γpromotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546969" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : PPAR-γaction: it's all in your head.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31862752" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517853" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20656674" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20656674" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25621136" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219007" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431595" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thiazolidinediones and liver toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11092281" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11232013" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Rosiglitazone monotherapy is effective in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213884" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145742" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27088241" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423507" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816593" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22269613" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The cardiovascular effects of peroxisome proliferator-activated receptor agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848652" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17726191" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Avandia debate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179252" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505122" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983299" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983299" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983299" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501900" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501900" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17536074" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Thiazolidinediones and heart failure: a teleo-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17905165" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32024657" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029503" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690342" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584880" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17687124" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The rosiglitazone story--lessons from an FDA Advisory Committee meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17848653" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18613278" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636824" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rosiglitazone for type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679700" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31822895" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214598" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17466227" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17290029" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886418" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28246237" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29084736" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35253334" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35253334" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35253334" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745421" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9454525" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516220" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516221" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755495" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10937499" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Efficacy of troglitazone on body fat distribution in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical observations of weight gain associated with pioglitazone: 3 years</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505497" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220243" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153284" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007095" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901911" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Skeletal consequences of thiazolidinedione therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16608888" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Thiazolidinedione use and bone loss in older diabetic adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17264176" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363747" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443256" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Use of thiazolidinediones and fracture risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061432" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20631021" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Thiazolidinediones and fractures: evidence from translating research into action for diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19338377" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27935736" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500573" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Bone is a target for the antidiabetic compound rosiglitazone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947280" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Osteoclast progenitors reside in the peroxisome proliferator-activated receptorγ-expressing bone marrow cell population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15525588" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26109213" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26109213" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26197187" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28623552" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29476615" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9518284" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hepatic dysfunction associated with troglitazone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652997" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652998" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Troglitazone-induced hepatic failure leading to liver transplantation. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19670918" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157815" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19181303" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Glitazone use associated with diabetic macular edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22688528" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22688825" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16467508" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Rosiglitazone (Avandia) and macular edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587587" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effects of medical therapies on retinopathy progression in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21428766" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pioglitazone for diabetes prevention in impaired glucose tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997664" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21515846" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Incidence of diabetes following ramipril or rosiglitazone withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27465265" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
